BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9918562)

  • 1. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.
    Portier M; Rinaldi-Carmona M; Pecceu F; Combes T; Poinot-Chazel C; Calandra B; Barth F; le Fur G; Casellas P
    J Pharmacol Exp Ther; 1999 Feb; 288(2):582-9. PubMed ID: 9918562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.
    Bouaboula M; Desnoyer N; Carayon P; Combes T; Casellas P
    Mol Pharmacol; 1999 Mar; 55(3):473-80. PubMed ID: 10051530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SR144528 as inverse agonist of CB2 cannabinoid receptor.
    Rhee MH; Kim SK
    J Vet Sci; 2002 Sep; 3(3):179-84. PubMed ID: 12514329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
    Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
    J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.
    Felder CC; Joyce KE; Briley EM; Glass M; Mackie KP; Fahey KJ; Cullinan GJ; Hunden DC; Johnson DW; Chaney MO; Koppel GA; Brownstein M
    J Pharmacol Exp Ther; 1998 Jan; 284(1):291-7. PubMed ID: 9435190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.
    Lunn CA; Fine JS; Rojas-Triana A; Jackson JV; Fan X; Kung TT; Gonsiorek W; Schwarz MA; Lavey B; Kozlowski JA; Narula SK; Lundell DJ; Hipkin RW; Bober LA
    J Pharmacol Exp Ther; 2006 Feb; 316(2):780-8. PubMed ID: 16258021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses.
    Bouaboula M; Dussossoy D; Casellas P
    J Biol Chem; 1999 Jul; 274(29):20397-405. PubMed ID: 10400664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system.
    Rinaldi-Carmona M; Le Duigou A; Oustric D; Barth F; Bouaboula M; Carayon P; Casellas P; Le Fur G
    J Pharmacol Exp Ther; 1998 Dec; 287(3):1038-47. PubMed ID: 9864290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
    Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
    FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.
    Calandra B; Portier M; Kernéis A; Delpech M; Carillon C; Le Fur G; Ferrara P; Shire D
    Eur J Pharmacol; 1999 Jun; 374(3):445-55. PubMed ID: 10422789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
    Rhee MH; Vogel Z; Barg J; Bayewitch M; Levy R; Hanus L; Breuer A; Mechoulam R
    J Med Chem; 1997 Sep; 40(20):3228-33. PubMed ID: 9379442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
    Bouaboula M; Perrachon S; Milligan L; Canat X; Rinaldi-Carmona M; Portier M; Barth F; Calandra B; Pecceu F; Lupker J; Maffrand JP; Le Fur G; Casellas P
    J Biol Chem; 1997 Aug; 272(35):22330-9. PubMed ID: 9268384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
    Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z
    J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle.
    Holland M; John Challiss RA; Standen NB; Boyle JP
    Br J Pharmacol; 1999 Oct; 128(3):597-604. PubMed ID: 10516638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
    Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T
    J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice.
    Ueda Y; Miyagawa N; Matsui T; Kaya T; Iwamura H
    Eur J Pharmacol; 2005 Sep; 520(1-3):164-71. PubMed ID: 16153638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
    Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells.
    Zhang L; Tetrault J; Wang W; Loh HH; Law PY
    Mol Pharmacol; 2006 Jun; 69(6):1810-9. PubMed ID: 16525132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
    Mo FM; Offertáler L; Kunos G
    Eur J Pharmacol; 2004 Apr; 489(1-2):21-7. PubMed ID: 15063151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors.
    Govaerts SJ; Hermans E; Lambert DM
    Eur J Pharm Sci; 2004 Nov; 23(3):233-43. PubMed ID: 15489124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.